These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9159156)

  • 61. IGF-I and IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells.
    Rosendahl AH; Forsberg G
    Kidney Int; 2006 Nov; 70(9):1584-90. PubMed ID: 16969385
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
    Sinha S; Dwivedi N; Tao S; Jamadar A; Kakade VR; Neil MO; Weiss RH; Enders J; Calvet JP; Thomas SM; Rao R
    Oncogene; 2020 Feb; 39(6):1231-1245. PubMed ID: 31616061
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II.
    Ceda GP; Davis RG; Rosenfeld RG; Hoffman AR
    Endocrinology; 1987 Apr; 120(4):1658-62. PubMed ID: 3104015
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
    Varga JL; Schally AV; Csernus VJ; Zarándi M; Halmos G; Groot K; Rékási Z
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):692-7. PubMed ID: 9892695
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Control of leptin by metabolic state and its regulatory interactions with pituitary growth hormone and hepatic growth hormone receptors and insulin like growth factors in the tilapia (Oreochromis mossambicus).
    Douros JD; Baltzegar DA; Mankiewicz J; Taylor J; Yamaguchi Y; Lerner DT; Seale AP; Grau EG; Breves JP; Borski RJ
    Gen Comp Endocrinol; 2017 Jan; 240():227-237. PubMed ID: 27449341
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Int J Cancer; 1994 Oct; 59(1):51-5. PubMed ID: 7927904
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of human growth hormone on human pancreatic carcinoma growth, protein, and cell cycle kinetics.
    Harrison LE; Blumberg D; Berman R; Ng B; Hochwald S; Brennan MF; Burt M
    J Surg Res; 1996 Mar; 61(2):317-22. PubMed ID: 8656602
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 72. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.
    Rick FG; Seitz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Buchholz S; Block NL; Hohla F
    Cell Cycle; 2012 Nov; 11(22):4203-10. PubMed ID: 23095641
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
    Ning S; Trisler K; Wessels BW; Knox SJ
    Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
    Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
    Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
    Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Increase in mRNA concentrations of pituitary receptors for growth hormone-releasing hormone and growth hormone secretagogues after neonatal monosodium glutamate treatment.
    Kovacs M; Kineman RD; Schally AV; Flerko B; Frohman LA
    J Neuroendocrinol; 2000 Apr; 12(4):335-41. PubMed ID: 10718930
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation.
    Cheung CW; Vesey DA; Nicol DL; Johnson DW
    Kidney Int; 2004 Apr; 65(4):1272-9. PubMed ID: 15086466
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action.
    Kovács M; Halmos G; Groot K; Izdebski J; Schally AV
    Neuroendocrinology; 1996 Sep; 64(3):169-76. PubMed ID: 8875434
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Expression of the growth hormone/insulin-like growth factor axis during Balb/c thymus ontogeny and effects of growth hormone upon ex vivo T cell differentiation.
    Kermani H; Goffinet L; Mottet M; Bodart G; Morrhaye G; Dardenne O; Renard C; Overbergh L; Baron F; Beguin Y; Geenen V; Martens HJ
    Neuroimmunomodulation; 2012; 19(3):137-47. PubMed ID: 22261974
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
    Zarandi M; Varga JL; Schally AV; Horvath JE; Toller GL; Kovacs M; Letsch M; Groot K; Armatis P; Halmos G
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4610-5. PubMed ID: 16537407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.